QI
ALXN

QS Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

QS Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$1.3M Sell
7,072
-166
-2% -$28.5K 0.02% 426
2021
Q1 		$1.11M Sell
7,238
-567
-7% -$87.7K 0.01% 509
2020
Q4 		$1.22M Sell
7,805
-228
-3% -$29.3K 0.01% 437
2020
Q3 		$920K Sell
8,033
-202
-2% -$21.8K 0.01% 464
2020
Q2 		$925K Sell
8,235
-500
-6% -$53.1K 0.01% 745
2020
Q1 		$785K Hold
8,735
– – 0.01% 733
2019
Q4 		$942K Sell
8,735
-507
-5% -$54.2K 0.01% 794
2019
Q3 		$906K Hold
9,242
– – 0.01% 803
2019
Q2 		$1.21M Hold
9,242
– – 0.01% 746
2019
Q1 		$1.25M Sell
9,242
-280
-3% -$34.8K 0.01% 753
2018
Q4 		$928K Sell
9,522
-5,384
-36% -$636K 0.01% 783
2018
Q3 		$2.07M Sell
14,906
-6,457
-30% -$810K 0.02% 614
2018
Q2 		$2.65M Sell
21,363
-47
-0.2% -$5.49K 0.03% 512
2018
Q1 		$2.39M Sell
21,410
-36
-0.2% -$4.3K 0.02% 520
2017
Q4 		$2.56M Sell
21,446
-304
-1% -$37K 0.02% 518
2017
Q3 		$3.05M Sell
21,750
-1,675
-7% -$228K 0.02% 467
2017
Q2 		$2.85M Sell
23,425
-700
-3% -$81.5K 0.02% 486
2017
Q1 		$2.92M Sell
24,125
-2,749
-10% -$354K 0.03% 480
2016
Q4 		$3.29M Sell
26,874
-36
-0.1% -$4.41K 0.03% 461
2016
Q3 		$3.3M Sell
26,910
-867
-3% -$112K 0.03% 512
2016
Q2 		$3.24M Sell
27,777
-1,081
-4% -$153K 0.03% 519
2016
Q1 		$4.02M Sell
28,858
-9,799
-25% -$1.44M 0.04% 462
2015
Q4 		$7.37M Sell
38,657
-8,762
-18% -$1.53M 0.07% 259
2015
Q3 		$7.42M Sell
47,419
-315
-0.7% -$57.5K 0.08% 237
2015
Q2 		$8.63M Sell
47,734
-64,889
-58% -$11.2M 0.11% 234
2015
Q1 		$19.5M Sell
112,623
-77,058
-41% -$13.9M 0.22% 95
2014
Q4 		$35.1M Buy
189,681
+140,613
+287% +$26.1M 0.4% 50
2014
Q3 		$8.14M Sell
49,068
-500
-1% -$82.1K 0.22% 112
2014
Q2 		$7.75M Buy
49,568
+17,890
+56% +$2.82M 0.21% 120
2014
Q1 		$4.82M Buy
31,678
+24,600
+348% +$3.91M 0.15% 158
2013
Q4 		$942K Sell
7,078
-900
-11% -$108K 0.04% 327
2013
Q3 		$927K Sell
7,978
-28,722
-78% -$3.15M 0.04% 340
2013
Q2 		$3.4M Buy
+36,700
New +$3.54M 0.12% 219

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

QS Investors's ALXN Position: Q2 2021 in Review

QS Investors reduced its Alexion Pharmaceuticals (ALXN) stake by 2.3% in Q2 2021, selling an estimated $28.5K and leaving 7,072 shares worth $1.3M. The position accounts for 0.02% of the portfolio, ranked #426.

QS Investors first reported a position in ALXN in Q2 2013 and has held it in 33 quarters since. The position peaked at $35.1M in Q4 2014. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • QS Investors held 7,072 shares of Alexion Pharmaceuticals worth $1.3M as of Q2 2021.
  • QS Investors sold 166 Alexion Pharmaceuticals shares in Q2 2021, an estimated $28.5K.
  • Alexion Pharmaceuticals made up 0.02% of QS Investors's portfolio in Q2 2021, its #426 holding.
  • QS Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
  • QS Investors's Alexion Pharmaceuticals position peaked at $35.1M in Q4 2014.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.